Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Sep 26, 2022 1:37pm
152 Views
Post# 34987015

RE:RE:Volume

RE:RE:Volume

"The presentation is available only to attendees of the conference"

I don't think any of us are going to learn anything plus it doesn't sound like a company presentation more a general round table about cancer drug development. It is a bit odd, with all due respect, Paul is not a cancer expert. It's odd he got an invite. It smells like they wedged him in because there's something brewing more than for his cancer KOL status.



PWIB123 wrote: ZipTrader must have a strong following, because THTX got a mention about half way through his latest Youtube video, https://youtu.be/O6tkOY0GTVI, and the number of followers on StockTwits and the share price are rising.  Unfortunatley, he only highlighted the upcoming new  Torgarzo IV Push FDA approval.  I saw a poster on Stocktwits share this, and it seems to clearly be driving a short-term trading thesis.  Hopefully they'll learn more about the stock from the Cantor conference and hold.

 

<< Previous
Bullboard Posts
Next >>